Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders
NCT ID: NCT04221269
Last Updated: 2023-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
30 participants
INTERVENTIONAL
2020-12-01
2023-06-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cognitive Behavioral Suicide Prevention for Psychosis: Aim 2
NCT05345184
A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical Condition
NCT00525304
Assessment of the Efficacy of a Fatigue Management Therapy in Schizophrenia
NCT04332601
Mobile After-Care Support App: Pilot RCT
NCT03955250
Improving Cognition Via Exercise in Schizophrenia
NCT03270098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Enhanced Treatment as Usual
Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.
Enhanced Treatment as Usual
Routine community care plus assessment feedback reports to clinicians.
Coping Long-term with Active Suicide Program for Schizophrenia
Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.
Enhanced Treatment as Usual
Routine community care plus assessment feedback reports to clinicians.
Coping Long-term with Active Suicide Program for Schizophrenia
Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enhanced Treatment as Usual
Routine community care plus assessment feedback reports to clinicians.
Coping Long-term with Active Suicide Program for Schizophrenia
Adjunctive psychosocial intervention for suicide prevention involving in person, family, and phone sessions.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* diagnosis of a schizophrenia-spectrum disorder
* receiving pharmacotherapy
* 18 years or older
* speaks/reads English
Exclusion Criteria
* lack of phone access
* discharge to long-term facility
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
American Foundation for Suicide Prevention
OTHER
Butler Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brandon Gaudiano, PhD
Role: PRINCIPAL_INVESTIGATOR
Butler Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Butler Hospital
Providence, Rhode Island, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1908-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.